TY - JOUR
T1 - ARDS in the time of corona
T2 - context and perspective
AU - Voelkel, Norbert F.
AU - Bogaard, Harm Jan
AU - Kuebler, Wolfgang M.
PY - 2022/10/1
Y1 - 2022/10/1
N2 - For more than 2 years, COVID-19 has been holding the world at awe with new waves of infections, novel mutants, and still limited (albeit improved) means to combat SARS-CoV-2-induced respiratory failure, the most common and fatal presentation of severe COVID-19. In the present perspective, we draw from the successes and-mostly-failures in previous acute respiratory distress syndrome (ARDS) work and the experiences from COVID-19 to define conceptual barriers that have so far hindered therapeutic breakthroughs in this deadly disease, and to open up new avenues of thinking and thus, ultimately of therapy.
AB - For more than 2 years, COVID-19 has been holding the world at awe with new waves of infections, novel mutants, and still limited (albeit improved) means to combat SARS-CoV-2-induced respiratory failure, the most common and fatal presentation of severe COVID-19. In the present perspective, we draw from the successes and-mostly-failures in previous acute respiratory distress syndrome (ARDS) work and the experiences from COVID-19 to define conceptual barriers that have so far hindered therapeutic breakthroughs in this deadly disease, and to open up new avenues of thinking and thus, ultimately of therapy.
KW - ARDS
KW - COVID-19
KW - endothelial
KW - treatment
KW - ventilator-induced lung injury
UR - http://www.scopus.com/inward/record.url?scp=85139375348&partnerID=8YFLogxK
U2 - https://doi.org/10.1152/ajplung.00432.2021
DO - https://doi.org/10.1152/ajplung.00432.2021
M3 - Editorial
C2 - 35997290
SN - 1040-0605
VL - 323
SP - L431-L437
JO - American journal of physiology. Lung cellular and molecular physiology
JF - American journal of physiology. Lung cellular and molecular physiology
IS - 4
ER -